370. The Validity And Reliability Of The Turkish Version Of Bodi In A Retrospective Cohort

Background/ Objectives: Behçet’s synome Overall Damage Index (BODI) is a newly developed damage index specific to Behçet synome (BS). We aimed to evaluate validity, reliability and feasibility of the Turkish version of BODI and evaluate its performance for use in retrospective cohort studies for different phenotypes of BS. Methods: The study included 295 patients with at least 3 BODI scores out of 590 consecutive BS patients who were followed up between January 2015 and August 2017. Turkish version of the BODI form was developed by translating into Turkish and backwards by 2 people. BODI scores were calculated for each year during the follow-up period. The test-retest reliability of BODI was assessed by scoring the same 50 patients at 6-month intervals by the same observer (YYO). Two different observers (YYO- YO) assessed the same 50 patients for inter-observer agreement. The intra-class correlation coefficient (ICC) was used to assess the inter and intra-observer agreement. We also evaluated the median time to fill out the form in patients with different types of involvements. Results: Of 295 (158 F/137 M) patients, the mean age was 39 (9.9) and the mean follow-up time was 4.3 (1.3) years. Demographic features of BS patients were summarized in the Table. BODI median score was 1 (IQR=0-1). We observed an increased in BODI score in 111 (38%) patients during follow-up. The main reasons for increasing BODI scores were eye, vascular and neurological involvement (Table). The mean ICC for inter-observer agreement was 0.94 (95% CI, 0.89-0.96) and for intra-observer agreement was 1. The median (range) time to complete the form was 2 (1-8) minutes. Conclusions: This study showed that the Turkish version of BODI was a reliable and feasible instrument that could capture the change over time in damage, and could be used in retrospective cohort studies. Ocular involvement was the most common cause of progressive damage in this cohort. Disclosures: Gulen Hatemi has received grant/research support from Celgene and has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma. Yesim Ozguler has received honorariu for presentations from UCB Pharma, Novartis, and Pfizer. Vedat Hamuryudan has received grant/research support from Celgene and has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma. No other disclosures were reported